Shares of Verici Dx plc (LON:VRCI – Get Free Report) were up 11.1% during mid-day trading on Tuesday . The company traded as high as GBX 0.30 and last traded at GBX 0.25. 8,366,714 shares were traded during trading, an increase of 363% from the average daily volume of 1,806,996 shares. The stock had previously closed at GBX 0.23.
Verici Dx Stock Performance
The stock has a fifty day moving average of GBX 0.33 and a 200-day moving average of GBX 0.47. The company has a debt-to-equity ratio of 3.03, a quick ratio of 8.49 and a current ratio of 3.94. The company has a market cap of £5.72 million, a PE ratio of -0.28 and a beta of 1.26.
About Verici Dx
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Further Reading
- Five stocks we like better than Verici Dx
- Cleared for Takeoff: Archer Aviation Changes the Math on eVTOL
- Voyager Technologies: Space Force Deal Fuels Growth Despite Heavy Cash Burn
- Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?
- GE Vernova’s AI Power Boom Faces a Profit Test
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
